Biblio

Author Title Type [ Year

]

Filters: Author is Mattsson, Jonas [Clear All Filters]

2024

Moya TAlfaro, Salas MQueralt, Carreira ASantos, Atenafu EG, Law ADatt, Lam W, Pasic I, Kim DDong Hwan, Michelis FV, Basso INovitzky, et al. Dual T cell depletion for graft versus host disease prevention in peripheral blood haploidentical hematopoietic cell transplantation for adults with hematological malignancies. Bone Marrow Transplant. 2024.

Lucero J, Alhumaid M, Novitzky-Basso I, Capo-Chichi J-M, Stockley T, Gupta V, Bankar A, Chan S, Schuh AC, Minden M, et al. Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2024.

Murray A, Linn SMar, Yu B, Novitzky-Basso I, Mattsson J, Kennah M, Elemary M, White J, Lemieux C, Jamani K, et al. Real-world experience with ruxolitinib therapy for steroid-refractory acute graft versus host disease. Bone Marrow Transplant. 2024.

2023

Pereira MPinto, Remberger M, Chen C, Gerbitz A, Kim DDong Hwan, Kumar R, Lam W, Law ADatt, Lipton JH, Michelis FV, et al. Choosing between older matched sibling donor and younger matched unrelated donor in allogeneic hematopoietic cell transplantation: comparison of clinical outcomes in acute myeloid leukemia and myelodysplastic syndrome. Transplant Cell Ther. 2023.

Granton J, Novitzky-Basso IN, Binnie A, Mattsson J. Decidual stromal cells for the treatment of severe COVID-19 ARDS. Intensive Care Med. 2023.

Moya TAlfaro, Mattsson J, Remberger M, Lipton JH, Kim DD, Viswabandya A, Kumar R, Lam W, Law AD, Gerbitz A, et al. Influence of conditioning regimen intensity on outcomes post-allogeneic hematopoietic cell transplantation for acute myeloid leukemia in complete morphological remission. Eur J Haematol. 2023.

Nampoothiri RVasudevan, Tang K, Schuh A, Lam W, Maze D, Michelis FV, Chan S, Gupta V, Kim D, Kumar R, et al. Mutational Profile, Outcomes, and Impact of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia and Inconclusive Cytogenetic Analysis. Eur J Haematol. 2023.

Al-Shaibani E, Novitzky-Basso I, Mattsson J, Kim DDong Hwan. Post-transplant maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation harmonizing multiple therapeutic modalities including targeted therapy, immunotherapy and cellular therapy. Int J Hematol. 2023.

Novitzky-Basso I, Patriquin C, Linn SMar, Chiarello C, Pasic I, Lam W, Law A, Michelis FV, Gerbitz A, Viswabandya A, et al. Propensity score matching analysis comparing the efficacy and steroid tapering benefit of extracorporeal photopheresis to best available therapy in third-line or beyond treatment for chronic GvHD. Transplant Cell Ther. 2023.

Schain F, Boissin C, Laczik T, Fedeli S, Remberger M, Blennow O, Dykes J, Eich T, Jones C, Mattsson J, et al. Real-world clinical characterization, healthcare resource utilization and productivity loss in chronic graft versus host patients exposed to extracorporeal photopheresis in Sweden. Transfus Apher Sci. 2023:103705.

Linn SM, Novitzky-Basso I, Abduljalil O, Pasic I, Lam W, Law A, Michelis FV, Gerbitz A, Viswabandya A, Lipton J, et al. A Single-center, Real-world Experience of Chronic GVHD Treatment Using Ibrutinib, Imatinib, and Ruxolitinib and its Treatment Outcomes. Hematol Oncol Stem Cell Ther. 2023;17(1):60-71.

Schoutrop E, Poiret T, El-Serafi I, Zhao Y, He R, Moter A, Henriksson J, Hassan M, Magalhaes I, Mattsson J. Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models. J Immunother Cancer. 2023;11(2).

Madsen K, Lee K, Chen S, Chen C, Law ADatt, Gerbitz A, Kumar R, Kim D, Lam W, Pasic I, et al. Weight loss post-allogeneic stem cell transplant is associated with increased transplant-related mortality. Support Care Cancer. 2023;31(10):564.

2022

Nampoothiri RVasudevan, Pasic I, Law ADatt, Lam W, Chen C, Michelis FV, Kim DDong Hwan, Gerbitz A, Lipton JHoward, Kumar R, et al. Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Therapy-Related Hematologic Malignancies Developing After Multiple Myeloma. Eur J Haematol. 2022.

2021

Novitzky-Basso I, Remberger M, Chen C, Ellison C, Pasic I, Lam W, Law A, Gerbitz A, Viswabandya A, Lipton JH, et al. Anti-thymocyte Globulin and Post-Transplant Cyclophosphamide do not abrogate the inferior outcome risk conferred by human leukocyte antigen-A and -B mismatched donors. Eur J Haematol. 2021.

Novitzky-Basso I, Remberger M, Chen C, Pasic I, Lam W, Law A, Gerbitz A, Viswabandya A, Lipton JH, Kim DD, et al. ATG and Post-transplant Cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts. Eur J Haematol. 2021.

Linn SMar, Nampoothiri RVasudevan, Chen C, Pasic I, Al-Shaibani Z, Lam W, Law ADatt, Michelis FV, Kim DDH, Gerbitz A, et al. Outcomes of patients diagnosed with chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation: Results from a tertiary care center. Hematol Oncol Stem Cell Ther. 2021.

Basso INovitzky, AlHayli S, Shin E, Pasic I, Al-Shaibani Z, Lam W, Law A, Michelis F, Gerbitz A, Viswabandya A, et al. Refined hepatic grading system in chronic graft-versus-host disease improves prognostic risk stratification of long-term outcomes. Eur J Haematol. 2021.

2020

Mårtensson T, Szakos A, Mellgren K, Toporski J, Arvidson J, Mattsson J, Gustafsson B, Casswall TH. Diagnostic disagreement between clinical standard histopathological- and retrospective assessment of histopathology-based gastrointestinal graft-versus-host disease in children. Pediatr Transplant. 2020:e13824.

Alotaibi AS, Prem S, Chen S, Lipton JH, Kim DD, Viswabandya A, Kumar R, Lam W, Law AD, Mattsson J, et al. Fresh versus Frozen Allogeneic Peripheral Blood Stem Cell Grafts: a Successful Timely Option. Am J Hematol. 2020.

Salas MQueralt, Lam SChenc Wils, Pasic I, Gerbitz A, Michelis FV, Kim DDong Hwan, Al-Shaibani Z, Lipton JHoward, Mattsson J, Kumar R, et al. Less is More: Superior GVHD-Free/Relapse-Free Survival with Reduced Intensity Conditioning and Dual T-cell Depletion in AML. Biol Blood Marrow Transplant. 2020.

Cheng G-S, Selwa KE, Hatt C, Ram S, Fortuna AB, Guerriero M, Himelhoch B, McAree D, Hoffman TC, Brisson J, et al. Multicenter Evaluation of Parametric Response Mapping as an Indicator of Bronchiolitis Obliterans Syndrome After Hematopoietic Stem Cell Transplantation. Am J Transplant. 2020.

Legert KGarming, Ringdén O, Remberger M, Törlén J, Mattsson J, Dahllöf G. Oral mucositis after tacrolimus/sirolimus or cyclosporine/methotrexate as graft-versus-host disease prophylaxis. Oral Dis. 2020.

Nampoothiri RVasudevan, Chen S, Pasic I, Al-Shaibani Z, Lam W, Michelis FV, Kim DDong Hwan, Viswabandya A, Gerbitz A, Lipton JHoward, et al. Outcomes of adult patients with acute myeloid leukemia and unsuccessful cytogenetic analysis undergoing allogeneic hematopoietic stem cell transplantation. Hematol Oncol Stem Cell Ther. 2020.

Alanazi W, Chen S, Lipton JH, Kim DD, Viswabandya A, Kumar R, Lam W, Law AD, Al-Shaibani Z, Mattsson J, et al. Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. Acta Haematol. 2020:1-8.

Pages